Ironwood and Allergan settle patent dispute with Indian major

17 January 2018
drugs_pills_tablets_big

Drugmakers Ironwood Pharmaceuticals (Nasdaq: IRWD) and Allergan (NYSE: AGN) have reached an agreement with wholly-owned subsidiaries of India’s Sun Pharmaceutical Industries (BSE: 524715) resolving patent litigation brought in response to Sun Pharma’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Linzess (linaclotide) prior to the expiration of the companies’ applicable patents.

Under the terms of the settlement, Ironwood and Allergan will grant the wholly-owned subsidiaries of Sun Pharma a license to market a generic version of Linzess in the USA beginning on February 1, 2031 (subject to US Food and Drug Administration approval), unless certain limited circumstances, customary for settlement agreements of this nature, occur. As a result of the settlement, all Hatch-Waxman litigation between the companies and Sun Pharma regarding Linzess patents will be dismissed. Additional details regarding the settlement were not disclosed.

Linaclotide is indicated for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).Allergan’s third-quarter 2017 sales of Linzess (linaclotide) were $190.9 million, a year-on-year increase of 16.1%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics